Glucagon receptor activity distinguishes retatrutide’s target profile from that of tirzepatide and semaglutide. Research on the combined profile includes effects on body weight and metabolic measures.
A third receptor under study
The liver-fat substudy measured an outcome of treatment with the complete molecule. Its design did not estimate how much of that change came from glucagon receptor activity by itself.
How to interpret the evidence
Separate the observed clinical outcome from explanations proposed for that outcome. A mechanistic interpretation should follow the experiments that actually tested it.
Start with the intervention name and receptor targets, then follow the links to the original trial if you want to check what was measured in people.